Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immunzellkalender 2025
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English
Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER
MS Treatments
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Ziemssen T, Posevitz-Fejfár A, Chudecka A, Cepek L, Reifschneider G, Grothe C, Richter J, Wagner T, Müller B, Penner IK.
Verlag
Publisher-Information
Mult Scler Relat Disord. 2024 Aug 10;90:105812.
Link
Zur Publikation (externer Server)
https://doi.org/10.1016/j.msard.2024.105812
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
MSZ
Treatments
2024
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
MS Treatments
Jahr
2025
RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis
MASC
Jahr
2025
Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment
Mobility
Jahr
2025
A roadmap for safe, regulation-compliant Living Labs for AI and digital health development
MASC
Jahr
2025
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
MASC
Jahr
2025